Bet v 1 Target Deep Dive
Allergen Blocking
Biological Context
Bet v 1 is the major allergen of birch pollen (Betula verrucosa) and the primary driver of spring pollen allergies in northern Europe and much of North America. More than 95% of birch-allergic patients are sensitized to Bet v 1, and cross-reactivity with homologous PR-10 proteins in apple, hazelnut, celery, and carrot is the molecular basis of the oral allergy syndrome that many birch-allergic patients experience with these foods.
Why it matters: Allergic reactions are triggered when patient IgE antibodies cross-link Bet v 1 on mast cells and basophils. Conventional allergen immunotherapy works by repeated exposure to progressively increase IgG4 (blocking antibodies) that compete with IgE for epitope binding. A designed “masking” binder that specifically covers the immunodominant IgE epitopes of Bet v 1 could prevent IgE engagement without the years of subcutaneous or sublingual desensitization that conventional immunotherapy requires. This is a frontier for protein design and a genuine translational opportunity.
The Goal: Design a binder that covers one or more of the major IgE epitopes on Bet v 1, blocking IgE cross-linking.
Interactive Structure
The viewer below shows the structure of Bet v 1 (PDB 4A88, isoform Bet v 1.0101).
Non-interactive alternative: The target-specification table below describes the relevant chain and epitope residues. You can also open the 4A88 structure record or download its PDB coordinates. Manipulating the 3D viewer is optional.
- Rotate: Left-click and drag
- Zoom: Scroll wheel
- Pan: Right-click (or Ctrl+Left-click) and drag
Design Mission
Design a protein that binds tightly to a solvent-exposed surface of Bet v 1, preferably covering one of the major IgE epitopes. Unlike the cytokine-receptor targets, there’s no single natural partner to mimic — your binder is functionally a surrogate blocking antibody.
Target Specifications
| Feature | Detail |
|---|---|
| Target Name | Bet v 1.0101 (major birch pollen allergen) |
| PDB ID | 4A88 |
| Target Chain | Chain A |
| Published E45 evidence | E45S abolished binding to the murine monoclonal antibody BV16 and reduced patient-serum IgE binding by roughly 25–50% in the reported assays (Spangfort et al. 2003) |
| Published IgE epitope residues (Mirza 2000, Spangfort 2003, Gepp 2014) | E8, T10, D27, K32, E42, N43, E45, N47, K55, K65, E73, N78, Y83, K97, D109, K123, E127, K134 — dispersed across the surface in at least three conformational patches |
| IgE epitope patch 1 (P-loop face) | E8, T10, D27, K32, E42, E45, N47 — centered on E45 |
| IgE epitope patch 2 (opposite face) | E73, N78, Y83, K97, D109 |
| IgE epitope patch 3 (C-terminal helix) | K123, E127, K134 |
These epitope residues are compiled from antibody–Bet v 1 co-crystal structures and mutational mapping (Mirza 2000 for the BV16 Fab complex and Spangfort 2003 for E45S). The 4A88 deposition is apo Bet v 1, so the residues come from cited experiments rather than proximity to a partner in 4A88. E45 is a well-supported residue in the BV16-centered patch, but patient IgE responses are heterogeneous and several conformational epitopes contribute. Covering E45 is therefore a testable competition hypothesis, not proof of broadly reduced IgE binding.
Strategy Tips
- Download PDB
4A88. - Pick a patch: Patch 1 (the P-loop / E45 face) is a well-characterized starting hypothesis, but compare it with at least one other surface patch because patient IgE repertoires vary.
- Define hotspots: Pass 4–6 residues from your chosen patch (e.g.,
A10,A42,A45,A47) to RFdiffusion / BindCraft. - Be honest about competition: A real therapeutic would need to out-compete patient-derived IgE for these same residues. Your computational design won’t be tested against real IgE in the capstone, but you should at least confirm (via AlphaFold2 or Chai-1) that the designed binder places its paratope directly over E45.
- Consider pocket binding: Bet v 1 has a large internal hydrophobic cavity (the PR-10 “Y-shaped” cavity) that binds various physiological ligands. Ligand binding causes subtle conformational changes that may affect IgE recognition — binders that stabilize an “IgE-hiding” conformation are a more speculative but intriguing strategy.
Reference
- Spangfort, M.D. et al. (2003). Dominating IgE-binding epitope of Bet v 1, the major allergen of birch pollen, characterized by X-ray crystallography and site-directed mutagenesis. J. Immunol. 171, 3084–3090. doi:10.4049/jimmunol.171.6.3084
- Mirza, O. et al. (2000). Dominant epitopes and allergic cross-reactivity: complex formation between a Fab fragment of a monoclonal murine IgG antibody and the major allergen from birch pollen Bet v 1. J. Immunol. 165, 331–338. doi:10.4049/jimmunol.165.1.331
- Kofler, S. et al. (2012). Crystallographically mapped ligand binding differs in high and low IgE binding isoforms of birch pollen allergen Bet v 1. Journal of Molecular Biology 422, 109–123. doi:10.1016/j.jmb.2012.05.016 — primary citation for 4A88.